Combination Therapy & Drug Resistance
TNBC – Triple-Negative Breast Cancer – accounts for approximately 20 percent of all breast cancer patients and can be divided into distinct molecular subtypes with different prognosis, metastatic patterns, and responses to treatments.
Leave a Reply